Advertisement
News
Subscribe to Pharmaceutical Processing News

The Lead

Family Gets $6.75M in Botox Treatment Case

November 21, 2014 | by DAVE GRAM, Associated Press | Comments

A New York couple who said Botox treatment of their son's cerebral palsy left him with life-threatening complications and sued its manufacturer won a $6.75 million verdict from a federal jury on Thursday.        

TOPICS:

EMA: No Consistent Evidence of an Increased Risk of Heart Problems with Testosterone Medicines

November 21, 2014 8:13 am | Comments

The CMDh, a regulatory body representing EU Member States, has agreed by consensus that there is no consistent evidence of an increased risk of heart problems with testosterone medicines in men who lack the hormone (a condition known as hypogonadism).

TOPICS:

German Court: e-Cigarette Liquids Not Medicines

November 20, 2014 3:32 pm | Comments

A German federal court has ruled that the liquids contained in e-cigarettes aren't medicinal products and can be sold freely.                     

TOPICS:

FDA Approves Hard-to-Abuse Hydrocodone Pill

November 20, 2014 3:27 pm | by MATTHEW PERRONE, AP Health Writer | Comments

Federal health regulators have approved the first hard-to-abuse version of the painkiller hydrocodone, offering an alternative to a similar medication that has been widely criticized for lacking such safeguards.       

TOPICS:
Advertisement

Anthera and Patheon Sign Manufacturing Agreement for Liprotamase Phase III Registration Trial

November 20, 2014 11:23 am | Comments

Anthera Pharmaceuticals has signed a manufacturing and supply agreement with the Patheon division of DPx Holdings B.V.  The contract provides for Patheon to support the production of the Sollpura clinical drug product for Anthera's Phase III registration trial.

TOPICS:

Cystic Fibrosis Foundation Sells $3.3B in Vertex Drug Royalties

November 20, 2014 8:48 am | Comments

The Cystic Fibrosis Foundation says it has sold royalty rights worth $3.3B for innovative drugs it helped develop with Vertex Pharmaceuticals. The drug rights were acquired by Royalty Pharma, which owns royalty rights to 40 pharmaceutical medicines.

TOPICS:

Vetter Opens Singapore Office to Support Growing Asian Healthcare Market

November 20, 2014 8:42 am | Comments

Vetter has announced the opening of a new representative office in Singapore. The announcement was made at a ceremony attended by members of local government agencies and a number of executives of pharmaceutical/biotech companies with a presence in the Asian region, as well as Vetter executives.

TOPICS:

Soaring Generic Drug Prices Draw Senate Scrutiny

November 20, 2014 8:35 am | by MATTHEW PERRONE, AP Health Writer | Comments

Some low-cost generic drugs that have helped restrain health care costs for decades are seeing unexpected price spikes of up to 8,000 percent, prompting a backlash from patients, pharmacists and now Washington lawmakers.     

TOPICS:

McKinsey Report Says Obesity Costs Hit $2T

November 20, 2014 8:19 am | Comments

A new report by the McKinsey Global Institute says that the global cost of obesity has risen to $2 trillion annually — nearly as much as smoking or the combined impact of armed violence, war and terrorism.        

TOPICS:
Advertisement

WHO: Ebola Transmission 'Intense' in Sierra Leone

November 20, 2014 8:12 am | by CLARENCE ROY-MACAULAY, Associated Press | Comments

The spread of Ebola remains "intense" in most of Sierra Leone even as things have improved somewhat in the two other countries hardest hit, the World Health Organization says. Some 168 new confirmed cases emerged in a single week in Sierra Leone's capital of Freetown recently, according to a WHO report.

TOPICS:

Dupilumab Receives FDA Breakthrough Therapy Designation in Atopic Dermatitis

November 20, 2014 8:09 am | Comments

Regeneron Pharmaceuticals and Sanofi have announced that the FDA has granted Breakthrough Therapy designation to dupilumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD) who are not adequately controlled with topical prescription therapy and/or for whom these treatments are not appropriate.

TOPICS:

Apellis Pharmaceuticals to Acquire Potentia Pharmaceuticals

November 20, 2014 8:00 am | Comments

Apellis Pharmaceuticals has entered into an agreement to acquire Potentia Pharmaceuticals. As part of the acquisition agreement, Apellis obtained the necessary intellectual property rights to develop its complement inhibitor drug compound (APL-2) in ophthalmology and plans its first clinical trial in dry age-related macular degeneration.

TOPICS:

Early Statin Use May Give Long-Term Heart Benefits

November 19, 2014 4:15 pm | by MARILYNN MARCHIONE, AP Chief Medical Writer | Comments

Taking a cholesterol-lowering drug for five years in middle age can lower heart and death risks for decades afterward, and the benefits seem to grow over time, a landmark study finds. Doctors say it's the first evidence that early use of a statin can have a legacy effect, perhaps changing someone's odds of disease for good.

TOPICS:

Government Wants More Clinical Trial Results Made Public

November 19, 2014 3:28 pm | by LAURAN NEERGAARD, AP Medical Writer | Comments

Doctors and patients may soon find it easier to learn if clinical trials of treatments worked or not, as the government proposed new rules Wednesday expanding what researchers are required to publicly report.       

TOPICS:

CDC Chief Drops Worst-Case Ebola Estimate

November 19, 2014 3:10 pm | by MIKE STOBBE, AP Medical Writer | Comments

The government's worst-case scenario forecast for the Ebola epidemic in West Africa won't happen, a U.S. health official said Wednesday. In September, the Centers for Disease Control and Prevention estimated the number of people sickened by the Ebola virus could explode to as many as 1.4 million by mid-January without more help.

TOPICS:

Shire to Relocate Over 500 Jobs to Massachusetts

November 19, 2014 2:04 pm | Comments

Shire has announced plans to relocate over 500 positions to Massachusetts from its Chesterbrook, Pennsylvania site and establish Lexington, Massachusetts as the company's U.S. operational headquarters. The transition is a continuation of the company's 'One Shire' efficiency program and will streamline business globally through two principal locations - Massachusetts and Switzerland.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading